These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 8661825)
1. Somatostatin receptor localization of pancreatic endocrine tumors. Corleto VD; Scopinaro F; Angeletti S; Materia A; Basso N; Polettini E; Annibale B; Schillaci O; D'Ambra G; Marignani M; Gualdi G; Bordi C; Passaro EJ; Delle Fave G World J Surg; 1996 Feb; 20(2):241-4. PubMed ID: 8661825 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Gibril F; Reynolds JC; Doppman JL; Chen CC; Venzon DJ; Termanini B; Weber HC; Stewart CA; Jensen RT Ann Intern Med; 1996 Jul; 125(1):26-34. PubMed ID: 8644985 [TBL] [Abstract][Full Text] [Related]
3. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953 [TBL] [Abstract][Full Text] [Related]
4. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127 [TBL] [Abstract][Full Text] [Related]
5. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors]. Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. de Kerviler E; Cadiot G; Lebtahi R; Faraggi M; Le Guludec D; Mignon M Eur J Nucl Med; 1994 Nov; 21(11):1191-7. PubMed ID: 7859770 [TBL] [Abstract][Full Text] [Related]
7. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177 [TBL] [Abstract][Full Text] [Related]
8. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129 [TBL] [Abstract][Full Text] [Related]
10. Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study. King CM; Reznek RH; Bomanji J; Ur E; Britton KE; Grossman AB; Besser GM Clin Radiol; 1993 Dec; 48(6):386-91. PubMed ID: 8293643 [TBL] [Abstract][Full Text] [Related]